CompletedNCT04916899

Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program

Studying Tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Laboratorios Silanes S.A. de C.V.
Principal Investigator
Alberto Maldonado Hernández, MS.
Centro de Salud Colima
Intervention
Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol(drug)
Enrollment
47 enrolled
Eligibility
12 years · All sexes
Timeline
2014 – 2016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04916899 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials